Repositioning Candidate Details
| Candidate ID: | R1596 |
| Source ID: | DB16416 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Vilobelimab |
| Synonyms: | IFX-1; Vilobelimab |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Vilobelimab is under investigation in clinical trial NCT03895801 (Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis). |
| CAS Number: | 2250440-41-4 |
| Molecular Weight: | |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Vilobelimab is an inhibitor targeting C5a in human plasma which helps markedly alleviate systemic inflammatory responses, and is being investigated in patients with acute lung injury. This neutralizing antihuman antibody acts by blocking the activation of C5a and thereby inhibits granulocyte expression of CD11b. |
| Targets: | Complement C5 inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|